Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this multicenter, Phase II trial is to examine the role of a well-tolerated
novel agent, panitumumab, in combination with a modern platinum doublet regimen using
carboplatin and pemetrexed, in patients with advanced non-squamous wild type K-ras
non-small-cell lung cancer (NSCLC). If this treatment proves to be well tolerated and
associated with efficacy, this would provide rationale for further randomized studies.